ID   RB3823
AC   CVCL_ZF07
SY   RB 3823
DR   Wikidata; Q98128830
RX   PubMed=30584916;
RX   PubMed=32123578;
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; None_reported; -; Zygosity=- (PubMed=30584916).
CC   Miscellaneous: STR profile from personal communication of Bremner, Rod.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8
ST   D16S539: 11,14
ST   D21S11: 27,28
ST   D5S818: 10,11
ST   D7S820: 10,12
ST   TH01: 7,9.3
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C7541; Retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 19-12-24; Version: 7
//
RX   PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018;
RA   Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T.,
RA   Schramm A., Temming P., Steenpass L.;
RT   "Comprehensive characterization of RB1 mutant and MYCN amplified
RT   retinoblastoma cell lines.";
RL   Exp. Cell Res. 375:92-99(2019).
//
RX   PubMed=32123578; DOI=10.1038/s41420-020-0237-8; PMCID=PMC7026052;
RA   Aubry A., Yu T., Bremner R.;
RT   "Preclinical studies reveal MLN4924 is a promising new retinoblastoma
RT   therapy.";
RL   Cell Death Discov. 6:2.1-2.12(2020).
//